Business Context and Reporting Period
This Form 8-K Current Report was filed by Kura Oncology, Inc. on September 8, 2026. The filing discloses a material change in executive leadership, specifically the appointment of a new Chief Financial Officer effective as of the report date.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
Effective September 8, 2026, the Board of Directors appointed Jennifer Fulk as Chief Financial Officer, principal financial officer, and principal accounting officer. She replaces Troy E. Wilson, Ph.D., J.D. (as principal financial officer) and Thomas Doyle (as principal accounting officer).
Management Commentary and Compensation Arrangements
Ms. Fulk's employment agreement includes the following compensation terms:
- Base Salary: $550,000 annually.
- Discretionary Bonus: Up to 45% of base salary.
- Stock Options: 450,000 shares vesting over 4 years (25% at one-year anniversary, then monthly).
- Performance Stock Units (PSUs): 173,438 shares vesting in six installments based on net product revenue, clinical development, and regulatory approval milestones.
Severance Provisions:
- Standard Termination (without Cause/Good Reason): 12 months of base salary, 12 months of COBRA, and extended option exercise period.
- Change in Control Termination: 18 months of base salary, 150% of target bonus, 18 months of COBRA, full acceleration of equity awards, and extended option exercise period.
Investor Verification Checklist
- Verify the exact vesting commencement date for the 450,000 stock options granted to Ms. Fulk.
- Review the specific definitions of "Corporate Transaction," "Cause," and "Good Reason" within the Fulk Agreement to understand severance triggers.
- Confirm the specific net product revenue and clinical milestones required for the 173,438 PSUs to vest.
- Assess the impact of this leadership change on the company's ongoing clinical development and regulatory strategy.